Advisory Council on the Misuse of Drugs

The report reviews the evidence on the use and harms of the novel benzodiazepine ethylbromazolam and recommends control under the Misuse of Drugs Act 1971.

A review of the evidence on the use and harms of 2-benzyl benzimidazole (nitazene) and piperidine benzimidazolone (brorphine-like) opioids.

This report reviews drug use in ethnic minority groups and outlines recommendations for further data collection.

ACMD review into the use and harms of SSCs and THCA to identify compounds causing harm which are not captured by the current generic definition for cannabinoids.

An overview of work carried out by the Advisory Council on the Misuse of Drugs (ACMD) from January 2023 to December 2025.

Occupations, career history and interests of the members of the Advisory Council on the Misuse of Drugs (ACMD).

Letter to the the Minister for Policing and Crime from the Chair of the Advisory Council on the Misuse of Drugs (ACMD) discussing the ACMD work programme for 2026.

This response agrees with recommendations from the Advisory Council on the Misuse of Drugs (ACMD) in 3 reports about the control and scheduling of 5 medicines.

Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister for Policing and Crime Prevention, about the consideration of ganaxolone.

Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister for Policing and Crime Prevention, about zuranolone.

Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister for Policing and Crime Prevention, about 3 growth hormone agonists.

The report presents a review of etomidate and structurally related compounds and subsequent recommendations regarding their classification and scheduling.

This report considers the use, harms and control of carisoprodol, a muscle relaxant previously prescribed in the UK to treat muscle spasms.

Biographies of members of the Advisory Council on the Misuse of Drugs.

Following a 2025 government commission, the ACMD has carried out a review of the use and harms of ketamine.

Review of the evidence on the use and harms of xylazine, medetomidine and detomidine.

Government response to the ACMD's report on the consideration of barriers to research: part 2.

Report on the long-term prevention of drug use and related harms among young people.

Letter to the Home Secretary from the Chair of the Advisory Council on the Misuse of Drugs (ACMD) discussing the ACMD work programme for 2025.

ACMD has written an updated harms assessment describing the use and harms of synthetic cathinones following a government commission.

The government commissions the Advisory Council on the Misuse of Drugs (ACMD) to conduct an updated harms assessment of ketamine.

A document developed by the Advisory Council on the Misuse of Drugs (ACMD) to outline the governing process for preparing evidence-based advice.

Overview of the Advisory Council on the Misuse of Drugs' (ACMD) work from January 2020 to December 2022.

The Advisory Council on the Misuse of Drugs responds to the government on their proposal to amend the licensing regimen for industrial hemp.

The Advisory Council on the Misuse of Drugs has provided an updated harms assessment of alkyl nitrites.

The government responds to the ACMD's report on recently encountered novel benzodiazepines and related compounds.

Government response to the report by the Advisory Council on the Misuse of Drugs on acyl piperazine opioids, including 2-methyl-AP-237.

The government commissions the Advisory Council on the Misuse of Drugs (ACMD) to review the fees applicable under the hemp licensing regime.

ACMD work programme 2024 letter to the Home Secretary from the Chair of the Advisory Council on the Misuse of Drugs (ACMD).

A review of the evidence on the use, harms and prevalence of recently encountered uncontrolled novel benzodiazepines and related compounds (2024 update).

This report has considered the harms and control of 2-methyl-AP-237 and other closely related acyl piperazine opioids.

Government response to the report by the Advisory Council on the Misuse of Drugs on xylazine, medetomidine and detomidine.

Recommendations from the ACMD to reduce barriers to research for schedule 1 controlled drugs.

Report from the Advisory Council on the Misuse of Drugs (ACMD) on consumer cannabidiol (CBD) products.

The government responds to a report by the Advisory Council on the Misuse of Drugs and commissions Part 2 of work on barriers to research.

The government responds to a report by the Advisory Council on the Misuse of Drugs (ACMD) regarding NHS England proposals on electronic prescribing.

The Advisory Council on the Misuse of Drugs has undertaken a review of the availability and implementation of naloxone in the UK.

The Advisory Council on the Misuse of Drugs (ACMD) has provided advice on the scheduling of nitrous oxide.

Call for evidence from the Advisory Council on the Misuse of Drugs on the prevalence and drivers of powder cocaine use by young people and adults.

Government response to the ACMD review of the evidence on the use and harms of diphenidine.

Letter commissioning the Advisory Council on the Misuse of Drugs (ACMD) to work on a project to prevent drug use in children and young people.

Government response to the ACMD's review of the evidence on the use and harms of Cumyl-PeGaClone.

Letter from the Advisory Council on the Misuse of Drugs (ACMD) regarding electronic prescribing of controlled drugs proposal from NHS England.

The government commissions the Advisory Council on the Misuse of Drugs (ACMD) to review the harms of Xylazine and 2-Methyl-AP-237.

The government commissions the ACMD to conduct an updated harms assessment of synthetic cathinones.

The government responds to a report by the Advisory Council on the Misuse of Drugs (ACMD) regarding the classification and schedule of remimazolam (Byfavo).

Letter from the ACMD Nitrous Oxide working group to collect written evidence about the health and social harms of nitrous oxide.

Letter to the chair of the ACMD asking the council to conduct an updated assessment of the health and social harms of nitrous oxide.

Letter from the Advisory Council on the Misuse of Drugs (ACMD) on young people’s drug use.

The government’s response to the ACMD’s fentanyl report.

Report from the Advisory Council on the Misuse of Drugs (ACMD) on the classification and schedule of Remimazolam.

Letter to the chair of the ACMD inviting them to establish a working group to respond to the recent white paper on drug possession.

Letter from Advisory Council on the Misuse of Drugs (ACMD) to ministers, providing advice on independent prescribing of controlled drugs by paramedics.

Government response to the ACMD's advice on the prescribing of controlled drugs by paramedics and on the administration rights of morphine by injection for therapeutic radiographers.

Letter from ACMD to ministers, providing advice on the administration rights of morphine by injection for therapeutic radiographer independent prescribers.

Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister of State for Crime Reduction and Policing on the interim podiatrists supply proposal.

Provides a summary of the main issues the ACMD considered between January 2017 and December 2019.

Provides a summary of the main issues the ACMD considered between April 2013 and December 2016.

The government commissions the ACMD to advise on the appropriate classification and scheduling of Isotonitazene and related compounds.

The government responds to the ACMD reports on cannabis-based products for medicinal use (CBPMs) in humans.

Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister of State for Crime Reduction and Policing on Sunosi advice.

Barriers to Research working group calls for written evidence about barriers to legitimate research for controlled drugs, excluding synthetic cannabinoids.

A review of the evidence of use and harms of novel benzodiazepines.

A letter from the Minister of State for Fire and Policing to the ACMD, in response to the recommendation to Schedule Epidyolex.

Letter from the ACMD Barriers to Research working group to collect written evidence from researchers about barriers to legitimate research with controlled drugs.

Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Home Secretary advising on COVID-19 emergency measures to enable the supply of controlled drugs.

Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Home Secretary in response to the 6 January letter on GHB and GBL.

Letter to the Home Office regarding the appropriate Schedule for the cannabis-based product for medicinal use, Epidyolex, under the Misuse of Drugs Regulations 2001.

This report advises government on the number and nature of known fentanyl analogues, risk factors, pharmacology, toxic effects and misuse and associated harms.

Letter to the Home Secretary from the Chair of the Advisory Council on the Misuse of Drugs, outlining our self-commissioned workstreams planned for 2020.

A framework for the assessment of the impact of rescheduling cannabis-based products for medicinal use (CBPMs).

Report to the Minister for Crime Prevention, which recommends a revised generic description of ‘third generation’ synthetic cannabinoids.

Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Home Office about the future use and purpose of Temporary Class Drug Orders (TCDOs).

Report from the ACMD providing advice to the government on the changing age profile of people accessing drug treatment and the challenges faced by this cohort in the UK.

Report from the Advisory Council on the Misuse of Drugs (ACMD) on how to reduce drug-related harms that occur when people move between custody and the community.

Letter to the Home Office about the appropriate control mechanism for 2, 4-Dinitrophenol (DNP).

Interim advice to the Home Office regarding the legitimate use of controlled drugs in research and healthcare.

Further advice about the prescribing of controlled drugs by therapeutic radiographers.

The Advisory Council on the Misuse of Drugs response to the consultation by NICE on the draft scope of their guidance on cannabis-based products for medicinal use.

Independent report by the Advisory Council on the Misuse of Drugs (ACMD) investigates the risk factors to substance use-related problems and harms.

The chair of the Advisory Council on the Misuse of Drugs writes to Karen Bradley about Pregabalin and Gabapentin.

Further advice from the Advisory Council on the Misuse of Drugs (ACMD) to the Home Office about the scheduling of cannabis-derived medicinal products.

Advice from the Advisory Council on the Misuse of Drugs (ACMD) to the Home Office about the scheduling of cannabis-derived medicinal products.

The Advisory Council on the Misuse of Drugs has been asked to consider the appropriate scheduling of cannabis-related products.

The letter is a request for evidence for the ACMD’s “community-custody transitions” working group.

Letter to Victoria Atkins MP from the chair of the Advisory Council on the Misuse of Drugs outlining recommendations for amending the safe custody regulations.

Letter to the Home Secretary from the chair of the Advisory Council on the Misuse of Drugs, outlining their work programme for 2017 to 2019.

This report by the Advisory Council on the Misuse of Drugs investigates the increase of drug-related deaths in the UK.

This is the report of the review of the Advisory Council on the Misuse of Drugs undertaken by Sir David Omand in December 2010.

In March 2009 the former Home Secretary requested advice on legal highs and ‘Spice’ in particular. This report draws on much of the evidence…

ACMD 1-benzylpiperazine (BZP) Report (2008) Date: Thu May 21 10:15:17 BST 2009 Full Document ACMD 1-benzylpiperazine (BZP) Report (2008…